Dear Editor, We would like to thank Drs Roux and Ricard for their comments [1] . They mainly appraised that our study [2] was biased from the start because of the methodology. We disagree with them on this affirmation because this is not a bias, this is just a different research question. Clearly, our study design was not built to clarify the potential role of a preemptive antifungal therapy in patients colonised with Candida in order to reduce the incidence of ventilator-associated pneumonia (VAP). Actually our research program was based on the observation that in the context of a clinical suspicion of VAP, the presence of Candida in the endotracheal secretions was associated with increased morbidity and mortality [3, 4] . We have not been able to demonstrate any clinical or inflammatory status improvement of such patients with an antifungal treatment in the CANTREAT study [2] . The literature is generally concordant with a significant proinflammatory effect of Candida spp. in the lungs [5] . However, conflicting results have been obtained regarding the consequences of such Candida colonisation on impaired immune response, interaction with pulmonary pathogens and its clinical impact. Both negative and positive small clinical studies have been published [6] . Some recent studies on animals and humans support a potential role of Candida colonisation on subsequent bacterial pneumonia development [6, 7] . Consequently, we support the idea of a larger clinical trial looking at the effect of an antifungal therapy in patients colonised with Candida spp. trying to improve clinical outcome. Interestingly, their proposed study design is not in contradiction with our results and certainly has the potential to further explore the exact pathophysiological role of Candida spp. colonisation in the respiratory secretions.
